Gatavs implants ar islatravīru
Apskatīt komentārus (0)
29.07.2019
Starptautiskajā AIDS konferencē Meksikā izstāstīja par jaunu ierīci, kas uzrāda efektīvus rezultātus cīņā ar HIV infekciju. Tā ir plastikāta nūjiņa sērkociņa lielumā, kas satur jaunas zāles islatravīru, kas līdz šim bija pazīstamas kā EfdA vai MK-8591.
Nūjiņa ir jāievada zem pleca ādas. Preparāts izdalīsies pakāpeniski nelielās devās pēc noteikta laika intervāla. Zāles iesūksies ģenitāliju un anālās atveres audos, kur vairumā gadījumu sākas inficēšanās, un bloķēs fermentu, kas ir atbildīgs par imūndeficīta vīrusa DNS klonēšanu.
Farmācijas kompānija Merck apgalvo, ka islatravīrs ir desmit reizes efektīvāks par visiem šodien izmantotajiem līdzekļiem, jo tas nepieciešams nelielā daudzumā, kas samazina blakņu risku. Ar vienu implantu var pietikt visu gadu.
Pēc ierīces izstrādātāju domām, tā kļūs par lielisku risinājumu cilvēkiem, kas baidās inficēties ar HIV.
**********************
Source: NAM Aidsmap | Gus Cairns | «PrEP implant could last well over a year» | http://www.aidsmap.com/news/jul-2019/prep-implant-could-last-well-over-year |
<... Islatravir is the latest HIV drug name to be added to the ever-growing list of antiretrovirals. The drug formerly known as MK-8591 was the subject of one of the most keenly-awaited studies to be presented at this weeks 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. This showed that an implant containing it, which is inserted under the skin of the upper arm, should provide sustained levels of drug sufficient to prevent HIV infection for over a year.
Islatravir or MK-8591, originally called EFdA, has been developed by Merck (MSD), and is a new type of reverse transcriptase inhibitor which does not just block the transcription of HIV viral RNA into DNA that can be integrated into cells by acting as a fake genetic base, as other NRTIs do, but also locks HIVs reverse transcriptase enzyme into a conformation where it is more easily degraded by cellular processes. It has extraordinary affinity for reverse transcriptase and effectively stops viral replication at blood and intracellular levels 100 times lower than other HIV drugs, and with a half-life of as long as seven days, meaning that it could be dosed monthly. ...>
Atpakaļ